A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

NCT06612151 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

438

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: YL201
DRUG: topotecan hydrochloride for injection

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.